FDA approvalconf 0.70
kresladi — FDA approval
$RCKT · ROCKET PHARMACEUTICALS, INC. · Treatment of pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) due to biallelic variants in ITGB2 without an available human leukocyte antigen-matched sibling donor for allogeneic hematopoietic stem cell transplant
Event date
Date TBD
Sponsor runway
10 mo
$144.4M liquid
Evidence
Comparable historical fda approvals· last 5 years · same event type
100% hit rate (10/10)
| Ticker | Drug | Date | Outcome |
|---|---|---|---|
| $INCY | zynyz | 2026-05-18 | success |
| $INCY | jakafi xr | 2026-05-01 | success |
| $AXSM | auvelity | 2026-04-30 | success |
| $INCY | zynyz | 2026-03-30 | success |
| $BIIB | spinraza | 2026-03-27 | success |
| $CORT | lifyorli | 2026-03-25 | success |
| $RYTM | imcivree | 2026-03-19 | success |
| $ASND | yuviwel | 2026-02-27 | success |
| $BMRN | palynziq | 2026-02-27 | success |
| $ETON | desmoda | 2026-02-25 | success |
Recent insider activity· ±90 days
4 insiders · 0 buys · 7 sells
Sell
2026-05-19Wilson Martin
General Counsel
662 @ $3.01$2K
Sell
2026-05-19Militello John
See Remarks
384 @ $3.01$1K
Sell
2026-05-19Shah Gaurav
CEO
2,409 @ $3.01$7K
Sell
2026-05-13Wilson Martin
General Counsel
3,361 @ $3.61$12K
Sell
2026-05-13Shah Gaurav
CEO
2,728 @ $3.61$10K
Sell
2026-05-13Militello John
See Remarks
855 @ $3.61$3K
Sell
2026-05-07Chaudhuri Sarbani
See Remarks
17,650 @ $3.84$68K